Clinical Trial

Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma. The goal is to improve clinical response by reversing the negative effects of NETs on immune function and CAR-T cells.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-02
Trial Details
NCT Number NCT07361224
Lead Sponsor Tel-Aviv Sourasky Medical Center
Conditions Large B-Cell Lymphoma (LBCL)
Enrollment 12 participants
Start Date 2026-05
Primary Completion 2027-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-01